[HTML][HTML] Current state of Alzheimer's fluid biomarkers
JL Molinuevo, S Ayton, R Batrla, MM Bednar… - Acta …, 2018 - Springer
Alzheimer's disease (AD) is a progressive neurodegenerative disease with a complex and
heterogeneous pathophysiology. The number of people living with AD is predicted to …
heterogeneous pathophysiology. The number of people living with AD is predicted to …
Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative
DP Veitch, MW Weiner, PS Aisen, LA Beckett… - Alzheimer's & …, 2019 - Elsevier
Introduction The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to
validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI is a multisite …
validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI is a multisite …
Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer's …
We developed an endophenotype disease module-based methodology for Alzheimer's
disease (AD) drug repurposing and identified sildenafil as a potential disease risk modifier …
disease (AD) drug repurposing and identified sildenafil as a potential disease risk modifier …
Role of tau protein in Alzheimer's disease: The prime pathological player
Alzheimer's disease (AD) is a prevalently found tauopathy characterized by memory loss
and cognitive insufficiency. AD is an age-related neurodegenerative disease with two major …
and cognitive insufficiency. AD is an age-related neurodegenerative disease with two major …
Microglial activation correlates in vivo with both tau and amyloid in Alzheimer's disease
Alzheimer's disease is characterized by the histopathological presence of amyloid-β
plaques and tau-containing neurofibrillary tangles. Microglial activation is also a recognized …
plaques and tau-containing neurofibrillary tangles. Microglial activation is also a recognized …
[HTML][HTML] Linking the amyloid, tau, and mitochondrial hypotheses of Alzheimer's disease and identifying promising drug targets
Z Fišar - Biomolecules, 2022 - mdpi.com
Damage or loss of brain cells and impaired neurochemistry, neurogenesis, and synaptic and
nonsynaptic plasticity of the brain lead to dementia in neurodegenerative diseases, such as …
nonsynaptic plasticity of the brain lead to dementia in neurodegenerative diseases, such as …
Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages
Tracking longitudinal tau tangles accumulation across the Alzheimer's disease continuum is
crucial to better understand the natural history of tau pathology and for clinical trials …
crucial to better understand the natural history of tau pathology and for clinical trials …
[HTML][HTML] In vivo quantification of neurofibrillary tangles with [18F]MK-6240
TA Pascoal, M Shin, MS Kang, M Chamoun… - Alzheimer's research & …, 2018 - Springer
Background Imaging agents capable of quantifying the brain's tau aggregates will allow a
more precise staging of Alzheimer's disease (AD). The aim of the present study was to …
more precise staging of Alzheimer's disease (AD). The aim of the present study was to …
Subthreshold amyloid predicts tau deposition in aging
Current approaches to the early detection of Alzheimer's disease (AD) rely upon classifying
individuals as “positive” or “negative” for biomarkers related to the core pathology of β …
individuals as “positive” or “negative” for biomarkers related to the core pathology of β …
The basis of cellular and regional vulnerability in Alzheimer's disease
Alzheimer's disease (AD) differentially and specifically affects brain regions and neuronal
cell types in a predictable pattern. Damage to the brain appears to spread and worsens with …
cell types in a predictable pattern. Damage to the brain appears to spread and worsens with …